AGP Executive Report
Last update: 12 hours agoRare disease breakthrough (Netherlands): Amsterdam UMC researchers report in The Lancet Neurology that guanabenz, an existing blood pressure drug, can slow progression of vanishing white matter, a rare fatal childhood brain disorder—fewer children became wheelchair-dependent and none died during the study period versus 5 in an international comparison group. Public health alert (Netherlands): RIVM confirms the Netherlands’ first locally acquired West Nile virus infection in a human blood donor since 2020; mild symptoms were reported, and Utrecht is designated a risk area with blood donations screened. Care access debate (Ireland, EU context): Irish politicians urge Biogen to consider a compassionate access programme for Friedreich’s ataxia after reimbursement was rejected due to cost and uncertainty around clinical efficacy. Science integrity (Netherlands-linked): The BMJ retracts a Netherlands-linked paper on COVID vaccines and excess deaths, citing misleading discussion and insufficient description of limitations; one author has resigned. Health tech market (Netherlands industry): A new report projects strong growth for surgical imaging through 2030, naming Philips among key players.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
